Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Eltrombopag to Improve Thrombocytopenia of MYH9-related Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 16 years or more~* Confirmed diagnosis of MYH9-related disease~* Average platelet count for the previous year less than 50x10e9/L~* Written informed consent~Exclusion Criteria:~* Diseases known to involve the risk of thromboembolic events (e.g. atrial fibrillation)~* History of thrombosis within 1 year~* Use of drugs that affect platelet function (including but not limited to, aspirin, clopidogrel or NSAIDS) or anti-coagulants~* Females who are pregnant or nursing (a negative pregnancy test in required before enrollment of fertile women)~* Formal refusal of any recommendation of a safe contraception~* Alcohol or drug addiction~* Altered renal function as defined by creatinine of 20 mg/L or more~* Any other disease or condition that by the advise of the responsible physician would make the treatment dangerous for the patient or would make the patient ineligible for the study, including physical, psychiatric, social and behavioral problems. HCV positivity and liver diseases will not be considered an exclusion criterion since a phase II study showed that eltrombopag was effective and safe in this patient population.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- eltrombopag (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).